Dermatology · Henderson, NV
NPI
1134289762
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
2839 St Rose Pkwy, Suite #100
Henderson, NV, 89052
Phone (702) 837-8988
Medicare paid, 2024
$639K
31,976 services
Medicare patients, 2024
1,642
Average age 76
Drug cost, 2024
$1.4M
1,082 prescriptions
Company payments, 2025
$11K
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Curt Samlaska was code J7345 (aminolevulinic acid hcl for topical administration, 10% gel, 10 mg), 25,000 times for 45 patients. In total Curt Samlaska billed 31,976 services in 50 codes, and Medicare paid $639K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-08-23.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J7345 Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 25,000 | 45 | $1.27 | $32K |
| 17004 Destruction Skin Lesion | Office | 2,535 | 1,142 | $119.51 | $303K |
| 99214 Office E&M - Established | Office | 1,310 | 780 | $88.87 | $116K |
| 17003 Destruction Skin Lesion | Office | 953 | 149 | $4.74 | $4,518 |
| 99213 Office E&M - Established | Office | 935 | 637 | $64.54 | $60K |
| 17000 Destruction Skin Lesion | Office | 280 | 214 | $45.35 | $13K |
| 99204 Office E&M - New | Office | 226 | 226 | $112.25 | $25K |
| 17110 Destruction Skin Lesion | Office | 166 | 65 | $84.72 | $14K |
| 96574 Skin | Office | 101 | 40 | $210.13 | $21K |
| 11302 Removal or Shaving of Skin Growth | Office | 90 | 71 | $92.84 | $8,356 |
| 99203 Office E&M - New | Office | 59 | 59 | $73.41 | $4,331 |
| 11312 Removal or Shaving of Skin Growth | Office | 52 | 43 | $108.27 | $5,630 |
| 10060 Skin | Office | 48 | 45 | $91.72 | $4,403 |
| 11311 Removal or Shaving of Skin Growth | Office | 33 | 31 | $90.83 | $2,997 |
| 96573 Skin | Office | 25 | 14 | $176.69 | $4,417 |
By year: 2022 $743K for 43,033 services; 2023 $697K for 42,016 services; 2024 $639K for 31,976 services.
Medicare prescription drug claims, 2024
In 2024, the drug Curt Samlaska prescribed most often to Medicare patients was Triamcinolone Acetonide, with 356 prescriptions and refills. In total Curt Samlaska wrote 1,082 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 356 | 369 | 202 | $3,307 |
| Ketoconazole Generic | 122 | 132 | 49 | $1,258 |
| Hydrocortisone Generic | 82 | 83 | 49 | $366 |
| Doxycycline Hyclate Generic | 80 | 101 | 30 | $2,685 |
| Clobetasol Propionate Generic | 47 | 48 | 25 | $3,000 |
| Doxycycline Monohydrate Generic | 37 | 39 | 13 | $705 |
| Skyrizi Risankizumab-Rzaa | 28 | 73 | Under 11 | $579K |
| Econazole Nitrate Generic | 27 | 27 | 18 | $977 |
| Valacyclovir Valacyclovir Hcl | 27 | 34 | 23 | $798 |
| Metronidazole Generic | 21 | 24 | 13 | $1,808 |
| Rinvoq Upadacitinib | 19 | 28 | Under 11 | $180K |
| Doxycycline Ir-Dr Doxycycline Monohydrate | 19 | 23 | Under 11 | $10K |
| Humira(Cf) Pen Adalimumab | 17 | 17 | Under 11 | $154K |
| Xeljanz Xr Tofacitinib Citrate | 16 | 24 | Under 11 | $136K |
| Hydroxychloroquine Sulfate Generic | 15 | 15 | Under 11 | $588 |
Brand drugs: 158 claims; generic drugs: 924 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Curt Samlaska $11K ($11K in general payments such as food, travel and fees) from 21 companies. The largest payer was Abbvie Inc. with $6,862.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 28 | $6,862 |
| UCB, Inc. UCB.BR | 15 | $1,686 |
| Galderma Laboratories, L.P. GALD.SW | 17 | $307 |
| Janssen Biotech, Inc. JNJ | 10 | $267 |
| Pfizer Inc. PFE | 14 | $238 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 13 | $220 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $196 |
| Lilly USA, LLC LLY | 3 | $179 |
| Arcutis Biotherapeutics, Inc. ARQT | 19 | $153 |
| LEO Pharma Inc. | 7 | $127 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.